Special situations: Intradialytic hypertension/chronic hypertension and intradialytic hypotension.
Van Buren PN, Inrig JK.
Semin Dial. 2017 Nov;30(6):545-552. doi: 10.1111/sdi.12631. Epub 2017 Jun 30.
Calcium channel blockers: differences between subclasses.
Frishman WH.
Am J Cardiovasc Drugs. 2007;7 Suppl 1:17-23. doi: 10.2165/00129784-200707001-00003.
Hypertension and Heart Failure: Prevention, Targets, and Treatment.
Di Palo KE, Barone NJ.
Cardiol Clin. 2022 May;40(2):237-244. doi: 10.1016/j.ccl.2021.12.011.
Diuretics in the treatment of hypertension.
Blowey DL.
Pediatr Nephrol. 2016 Dec;31(12):2223-2233. doi: 10.1007/s00467-016-3334-4. Epub 2016 Mar 16.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees.
Lancet. 2003 Sep 6;362(9386):772-6. doi: 10.1016/S0140-6736(03)14284-5.
What are the causes of the ill effects of chronic hemodialysis? Balancing risks: blood pressure targets, intradialytic hypotension, and ischemic brain injury.
Davenport A.
Semin Dial. 2014 Jan-Feb;27(1):13-5. doi: 10.1111/sdi.12153. Epub 2013 Oct 17.
New Horizons in orthostatic hypotension.
Frith J, Parry SW.
Age Ageing. 2017 Mar 1;46(2):168-174. doi: 10.1093/ageing/afw211.
Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke: multicentre, open label, randomised, controlled trial.
Liu L, Xie X, Pan Y, Wang A, Wei Y, Liu J, Nie X, Liu D, Zhao Z, Wang P, Shen S, Zhong C, Xu T, Wang D, Wang GC, Song D, Ma Y, Zhao J, Jiang Y, Jing J, Meng X, Obst K, Chen CS, Wang D, Wang Y, Zhang Y, Wang Y, He J; CATIS-2 Investigators.
BMJ. 2023 Oct 9;383:e076448. doi: 10.1136/bmj-2023-076448.
Geburtshilfe: hypertensive Erkrankungen in der Schwangerschaft.
Buddeberg BS, Girard T.
Anasthesiol Intensivmed Notfallmed Schmerzther. 2017 Mar;52(3):184-195. doi: 10.1055/s-0042-105990. Epub 2017 Mar 16.
Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.
He J, Ouyang N, Guo X, Sun G, Li Z, Mu J, Wang DW, Qiao L, Xing L, Ren G, Zhao C, Yang R, Yuan Z, Wang C, Shi C, Liu S, Miao W, Li G, Chen CS, Sun Y; CRHCP Study Group.
Lancet. 2023 Mar 18;401(10380):928-938. doi: 10.1016/S0140-6736(22)02603-4. Epub 2023 Mar 2.
